Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Sotorasib and adagrasib target a specific cancer-causing mutation found in those with non-small-cell lung cancer and colorectal cancer.
To take advantage of these new therapies, people must first learn whether their cancer harbors targetable mutations.
A novel drug that blocks multiple cancer-causing mutations shows promise, especially for combination therapy.
MRTX849 shrank tumors in half of lung cancer patients with a common but difficult to target mutation.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.